Skip to main content
U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Introduction

Thank you for your interest and participation in our study. We are looking at how the investigational drug, SRX246, affects human response to the threat of an unpleasant shock. Arginine vasopressin (AVP) is a hormone made in the body. It can make negative feelings stronger. Previous research has shown that the way AVP is regulated may be abnormal in people with mood and anxiety disorders. Research in animals has shown that AVP can cause anxious behavior. SRX246 is an investigational drug that can block one of the receptors for AVP in brain cells. In this study, we will look at the effect of SRX246 on the response to predictable and unpredictable shock. We will compare these effects to the effects of placebo, an inactive pill. Each participant in this study will receive SRX246 for one week and placebo for one week. Neither you nor the researchers will know when you are receiving SRX246 and when you are receiving the placebo. When you receive each one will be chosen by chance, like by flipping a coin.

SRX246 has been developed and will be supplied by Azevan Pharmaceuticals, Inc. It is not approved by the FDA for treatment of any disease or condition. The FDA has permitted the use of SRX246 in this study as an "investigational new drug."

To get started:

  • Navigate through the menu on your left to learn more about the study.
  • Log In the application and fill out questionnaires

Please contact us if you have any questions or concerns.